No abstract available
Keywords:
SGLT2 inhibitor; canagliflozin; cardiovascular disease; type 2 diabetes.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Canagliflozin / therapeutic use
-
Cardiovascular Diseases* / complications
-
Cardiovascular Diseases* / drug therapy
-
Cardiovascular Diseases* / prevention & control
-
Cardiovascular System*
-
Diabetes Mellitus, Type 2* / chemically induced
-
Diabetes Mellitus, Type 2* / complications
-
Diabetes Mellitus, Type 2* / drug therapy
-
Humans
-
Kidney
-
Peripheral Arterial Disease* / complications
-
Peripheral Arterial Disease* / drug therapy
-
Renal Insufficiency, Chronic* / chemically induced
-
Renal Insufficiency, Chronic* / complications
-
Renal Insufficiency, Chronic* / drug therapy